Cerus Corp develops and commercializes the INTERCEPT Blood System, a pathogen-reduction platform used to treat donated blood components before transfusion. The company’s core business is built around platelet, plasma, and red blood cell applications, with additional work in IFC and government-funded development programs. Cerus sells into blood banks, hospitals, and transfusion networks, and its commercial model relies heavily on distributors in many markets alongside direct sales in some territories. The company was founded in California and now operates with a U.S. base and a wholly owned European subsidiary, reflecting a business that is both regulated and globally distributed. Its long-term goal is to make INTERCEPT a standard-of-care technology for safer transfused blood products.
−3,1 %
−6,7 %
+16,1 %
1.73
1.17
| % | |
|---|---|
| Blood pathogen-reduction systems | 80% INTERCEPT systems used to inactivate pathogens and harmful cells in donated blood components before transfusion. |
| Disposable kits and consumables | 15% Single-use kits sold with the INTERCEPT platform and used in routine blood processing. |
| Device placements and illuminators | 3% Illuminator equipment and related installed-base support used to activate the INTERCEPT process. |
| Government and development revenue | 2% Revenue from government contracts and other development-related activities tied to product advancement. |
Cerus sells primarily to blood banks, transfusion centers, hospitals, and other healthcare organizations that process...
Buy INTERCEPT systems and disposable kits to treat donated blood components and reduce pathogen transmission risk before transfusion.
Purchase through direct or distributor channels to improve blood safety and support clinical protocols for transfused patients.
Buy and resell Cerus products in many territories, often holding local customer relationships and regulatory approvals.
Fund development, clinical studies, and other contract work that supports product advancement and regulatory progress.
The joint venture and local partner structure are intended to support future approval and commercialization in China.
Cerus is headquartered in the United States and derives a large share of its commercial opportunity from the U.S...
Cerus is focused on expanding commercial adoption of INTERCEPT in the U.S. while continuing to grow in approved...
The company depends heavily on commercial success in the U.S., so broader penetration is central to revenue growth and operating leverage.
A successful RBC launch would expand the addressable market and reduce reliance on the existing platelet and plasma franchise.
New geographies can diversify revenue, but require regulatory approvals, distributor execution, and local market access.
China could become a meaningful growth market if regulatory approval and cybersecurity requirements are met.
Cerus is highly dependent on the commercial success of INTERCEPT in the U.S., so slower-than-expected adoption would...
The company states that failure to commercialize INTERCEPT in the U.S. would have a material adverse effect on business, results, and growth prospects.
A concentrated number of distributors contribute a meaningful minority of product revenue, and transitions can disrupt customers and delay payments.
Approvals, CE certificates, and post-approval obligations can be time-consuming and can delay commercialization of new or enhanced products.
The JV cannot commercialize in China without regulatory approval, and the illuminator must satisfy current cybersecurity standards.
The company notes significant supply chain risk, which can affect product availability, cost, and the ability to meet demand.
CERS · Surgical & Medical Instruments & Apparatus
Cerus Corp develops and commercializes the INTERCEPT Blood System, a pathogen-reduction platform used to treat donated blood components before transfusion.
MEKO.ST · Consumer Discretionary
APOTEA.ST · Consumer Staples
KNOW.ST · Technology
NOBI.ST · Consumer Discretionary
METSO.HE · Farm & Heavy Construction Machinery
: 11/08/2026